EAM Investors LLC Sells 47,036 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

EAM Investors LLC reduced its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 26.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 128,923 shares of the biopharmaceutical company’s stock after selling 47,036 shares during the quarter. EAM Investors LLC’s holdings in TG Therapeutics were worth $3,881,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after purchasing an additional 209,190 shares in the last quarter. Clearbridge Investments LLC bought a new stake in TG Therapeutics during the fourth quarter valued at approximately $55,237,000. Charles Schwab Investment Management Inc. grew its stake in TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after buying an additional 84,904 shares in the last quarter. Invesco Ltd. increased its holdings in shares of TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock worth $27,985,000 after buying an additional 10,989 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of TG Therapeutics by 10.5% during the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock valued at $27,797,000 after buying an additional 87,679 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $39.03 on Wednesday. The company has a 50-day simple moving average of $35.98 and a two-hundred day simple moving average of $31.60. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of -390.26 and a beta of 2.14. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on TGTX shares. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.